At Canexia Health, we make high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support.
Only a small percentage of cancer patients receive genomic biomarker testing that could match them with targeted treatments demonstrated to improve outcomes. We pair the latest advances in oncology with machine learning to provide cancer professionals with the insights needed to make targeted treatment decisions for their patients.
Tailor treatment decisions based on somatic mutations in your patient’s tumor.
A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.
Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.
Make more informed treatment decisions by using detailed results for therapeutic recommendations and expertly curated clinical trials information provided in our comprehensive reporting software.
Conduct world-leading mutation assays for cancer patients, right from your laboratory. Our cloud-based analytics platform allows partner labs access to our proprietary informatics software suite covering the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation, and report generation.
“We have found the FIND-IT assay to be a reliable, quick and cost-effective tool for identifying driver mutations in fixed tissue samples from across Australia. This has had direct implications for identifying patients suitable for targeted therapies, especially those with lung cancer, colorectal cancer and melanoma. However, the scope of the test is such that there is also interest in the panel for patients with a variety of other cancers, including breast and endometrial cancers.” Professor Graeme Suthers, Sonic Genetics
January 11, 2021
With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test, which is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.
December 16, 2020
Earlier this year, Canexia Health launched Project ACTT, Access to Cancer Testing & Treatment in Response to COVID-19, with support from the Canadian federal government via the Digital Technology Supercluster. Through ACTT, we are leading a consortium of partners to speed up cancer testing in Canada for targeted treatment selection during the pandemic through minimally invasive circulating tumor (ctDNA) testing.
December 3, 2020
Canexia Health's Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
Canexia Health’s clinically-validated and cost-effective assays, informatics, and support offer a complete end-to-end solution, from mutation identification to auto-generated clinical reports.